Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month High - Here's What Happened

Key Points

• Supernus Pharmaceuticals shares reached a new 52-week high of $45.01, experiencing significant trading volume of 1,047,668 shares.
• Analyst ratings have shown a positive shift, with Cantor Fitzgerald raising the target price to $46.00 and upgrades from Zacks Research to a "hold" rating, contributing to an average rating of "Moderate Buy" with a consensus target price of $41.00.
• Insider transactions have occurred, with significant sales including CEO Jack A. Khattar offloading 140,000 shares valued at approximately $5.88 million, indicating notable insider movement within the company.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) shares hit a new 52-week high during trading on Monday . The company traded as high as $45.01 and last traded at $44.92, with a volume of 1047668 shares traded. The stock had previously closed at $43.32.

Analysts Set New Price Targets

A number of equities research analysts have commented on SUPN shares. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Cantor Fitzgerald lifted their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, Piper Sandler upped their price objective on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a report on Friday. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $43.00.

Supernus Pharmaceuticals Stock Down 0.6%

The firm has a 50 day moving average of $36.63 and a 200-day moving average of $33.94. The company has a market cap of $2.53 billion, a P/E ratio of 39.23 and a beta of 0.74.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, Director Frederick M. Hudson sold 7,457 shares of the firm's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the sale, the director owned 46,307 shares of the company's stock, valued at $1,956,933.82. This trade represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Frank Mottola sold 14,000 shares of the firm's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $44.51, for a total value of $623,140.00. Following the completion of the sale, the senior vice president directly owned 15,496 shares of the company's stock, valued at $689,726.96. The trade was a 47.46% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 179,606 shares of company stock worth $7,617,005. 8.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Raiffeisen Bank International AG purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth $25,000. Financial Management Professionals Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the first quarter worth about $30,000. Versant Capital Management Inc lifted its holdings in shares of Supernus Pharmaceuticals by 6,931.3% in the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after buying an additional 1,109 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Supernus Pharmaceuticals in the first quarter valued at approximately $41,000. Finally, GF Fund Management CO. LTD. purchased a new position in Supernus Pharmaceuticals in the fourth quarter valued at $42,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.